Titre : Oxygénation hyperbare

Oxygénation hyperbare : Questions médicales fréquentes

Termes MeSH sélectionnés :

Programmed Cell Death 1 Receptor
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Oxygénation hyperbare : Questions médicales les plus fréquentes", "headline": "Oxygénation hyperbare : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Oxygénation hyperbare : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-01-26", "dateModified": "2025-04-20", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Oxygénation hyperbare" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Oxygénothérapie", "url": "https://questionsmedicales.fr/mesh/D010102", "about": { "@type": "MedicalCondition", "name": "Oxygénothérapie", "code": { "@type": "MedicalCode", "code": "D010102", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "E02.880.690" } } }, "about": { "@type": "MedicalCondition", "name": "Oxygénation hyperbare", "alternateName": "Hyperbaric Oxygenation", "code": { "@type": "MedicalCode", "code": "D006931", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Richard E Moon", "url": "https://questionsmedicales.fr/author/Richard%20E%20Moon", "affiliation": { "@type": "Organization", "name": "Departments of Anesthesiology and Medicine, Center for Hyperbaric Medicine and Environmental Physiology, Duke University, North Carolina U.S." } }, { "@type": "Person", "name": "John P Kirby", "url": "https://questionsmedicales.fr/author/John%20P%20Kirby", "affiliation": { "@type": "Organization", "name": "John P. Kirby MD, FACS, is the Director of Wound Healing Programs, Associate Professor of Surgery, Section of Acute and Critical Care Surgery, at Washington University School of Medicine, Barnes-Jewish Hospital, in St. Louis, Missouri." } }, { "@type": "Person", "name": "Stephen R Thom", "url": "https://questionsmedicales.fr/author/Stephen%20R%20Thom", "affiliation": { "@type": "Organization", "name": "Emergency Medicine, University of Maryland, Baltimore, MD, USA." } }, { "@type": "Person", "name": "Michael H Bennett", "url": "https://questionsmedicales.fr/author/Michael%20H%20Bennett", "affiliation": { "@type": "Organization", "name": "Department of Diving and Hyperbaric Medicine, Prince of Wales Hospital and University of New South Wales, Sydney, New South Wales, Australia." } }, { "@type": "Person", "name": "Simon J Mitchell", "url": "https://questionsmedicales.fr/author/Simon%20J%20Mitchell", "affiliation": { "@type": "Organization", "name": "Department of Anaesthesiology, University of Auckland Faculty of Medicine, Auckland, New Zealand." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Programmed cell death-1 blockade therapy in melanoma: Resistance mechanisms and combination strategies.", "datePublished": "2023-01-24", "url": "https://questionsmedicales.fr/article/36645031", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/exd.14750" } }, { "@type": "ScholarlyArticle", "name": "MicroRNAs Targeting Programmed Cell Death Protein 1 (PD-1) Promote Natural Killer Cell Exhaustion in Rheumatoid Arthritis.", "datePublished": "2022-12-24", "url": "https://questionsmedicales.fr/article/36640056", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.18502/ijaai.v21i6.11524" } }, { "@type": "ScholarlyArticle", "name": "Differential expression of programmed death 1 (PD-1) on various immune cells and its role in human leprosy.", "datePublished": "2023-04-21", "url": "https://questionsmedicales.fr/article/37153623", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fimmu.2023.1138145" } }, { "@type": "ScholarlyArticle", "name": "A High Programmed Cell Death Protein 1 Hormone Receptor Score on Skin Biopsy is Associated with Sézary Syndrome Diagnosis: A Study of 91 Patients with Erythroderma.", "datePublished": "2022-09-06", "url": "https://questionsmedicales.fr/article/35758515", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.2340/actadv.v102.1062" } }, { "@type": "ScholarlyArticle", "name": "Functionalized biomimetic nanoparticles combining programmed death-1/programmed death-ligand 1 blockade with photothermal ablation for enhanced colorectal cancer immunotherapy.", "datePublished": "2022-11-25", "url": "https://questionsmedicales.fr/article/36442821", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.actbio.2022.11.043" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Thérapeutique", "item": "https://questionsmedicales.fr/mesh/D013812" }, { "@type": "ListItem", "position": 3, "name": "Thérapie respiratoire", "item": "https://questionsmedicales.fr/mesh/D012138" }, { "@type": "ListItem", "position": 4, "name": "Oxygénothérapie", "item": "https://questionsmedicales.fr/mesh/D010102" }, { "@type": "ListItem", "position": 5, "name": "Oxygénation hyperbare", "item": "https://questionsmedicales.fr/mesh/D006931" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Oxygénation hyperbare - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Oxygénation hyperbare", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-06", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Oxygénation hyperbare", "description": "Comment diagnostiquer une décompression ?\nQuels tests pour l'oxygénation hyperbare ?\nQuels symptômes indiquent un traitement ?\nComment évaluer l'efficacité du traitement ?\nQuels critères pour l'admission en chambre hyperbare ?", "url": "https://questionsmedicales.fr/mesh/D006931?mesh_terms=Programmed+Cell+Death+1+Receptor&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Oxygénation hyperbare", "description": "Quels sont les symptômes de l'oxygénation hyperbare ?\nComment se manifeste l'intoxication à l'oxygène ?\nQuels signes d'une embolie gazeuse ?\nQuels symptômes après une séance d'oxygénation ?\nComment reconnaître une réaction allergique ?", "url": "https://questionsmedicales.fr/mesh/D006931?mesh_terms=Programmed+Cell+Death+1+Receptor&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Oxygénation hyperbare", "description": "Comment prévenir la maladie de décompression ?\nQuelles précautions avant une séance ?\nComment éviter l'intoxication à l'oxygène ?\nQuelles sont les recommandations post-traitement ?\nComment se préparer psychologiquement ?", "url": "https://questionsmedicales.fr/mesh/D006931?mesh_terms=Programmed+Cell+Death+1+Receptor&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Oxygénation hyperbare", "description": "Quelles conditions traitent l'oxygénation hyperbare ?\nComment se déroule une séance d'oxygénation ?\nQuelle est la durée d'une séance ?\nY a-t-il des effets secondaires ?\nQui peut administrer ce traitement ?", "url": "https://questionsmedicales.fr/mesh/D006931?mesh_terms=Programmed+Cell+Death+1+Receptor&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Oxygénation hyperbare", "description": "Quelles complications peuvent survenir ?\nComment gérer une embolie gazeuse ?\nQuels risques liés à l'oxygénation hyperbare ?\nComment prévenir les infections en chambre ?\nQuels signes d'une complication grave ?", "url": "https://questionsmedicales.fr/mesh/D006931?mesh_terms=Programmed+Cell+Death+1+Receptor&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Oxygénation hyperbare", "description": "Quels sont les facteurs de risque de décompression ?\nQui est à risque d'intoxication à l'oxygène ?\nQuels antécédents augmentent les risques ?\nComment l'âge influence-t-il les risques ?\nQuels médicaments augmentent les risques ?", "url": "https://questionsmedicales.fr/mesh/D006931?mesh_terms=Programmed+Cell+Death+1+Receptor&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une décompression ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Un diagnostic de décompression se fait par l'évaluation des symptômes et des antécédents d'immersion." } }, { "@type": "Question", "name": "Quels tests pour l'oxygénation hyperbare ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests d'imagerie et des évaluations cliniques sont utilisés pour déterminer l'indication." } }, { "@type": "Question", "name": "Quels symptômes indiquent un traitement ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes comme des douleurs articulaires, des troubles neurologiques ou des brûlures peuvent indiquer un traitement." } }, { "@type": "Question", "name": "Comment évaluer l'efficacité du traitement ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "L'efficacité est évaluée par l'amélioration des symptômes et des tests de suivi après traitement." } }, { "@type": "Question", "name": "Quels critères pour l'admission en chambre hyperbare ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Les critères incluent des conditions médicales spécifiques et l'absence de contre-indications." } }, { "@type": "Question", "name": "Quels sont les symptômes de l'oxygénation hyperbare ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes peuvent inclure des douleurs, des vertiges, et des troubles de la vision." } }, { "@type": "Question", "name": "Comment se manifeste l'intoxication à l'oxygène ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "L'intoxication à l'oxygène se manifeste par des convulsions, des nausées et des troubles respiratoires." } }, { "@type": "Question", "name": "Quels signes d'une embolie gazeuse ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Les signes incluent des douleurs thoraciques, des difficultés respiratoires et des troubles neurologiques." } }, { "@type": "Question", "name": "Quels symptômes après une séance d'oxygénation ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Après une séance, des sensations de fatigue ou de légers maux de tête peuvent survenir." } }, { "@type": "Question", "name": "Comment reconnaître une réaction allergique ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Une réaction allergique peut se manifester par des éruptions cutanées, des démangeaisons ou un gonflement." } }, { "@type": "Question", "name": "Comment prévenir la maladie de décompression ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention inclut une ascension lente après la plongée et des pauses de sécurité." } }, { "@type": "Question", "name": "Quelles précautions avant une séance ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Évitez de fumer, de consommer de l'alcool et informez le médecin de vos antécédents médicaux." } }, { "@type": "Question", "name": "Comment éviter l'intoxication à l'oxygène ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Pour éviter l'intoxication, respectez les protocoles de traitement et les durées recommandées." } }, { "@type": "Question", "name": "Quelles sont les recommandations post-traitement ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Après traitement, reposez-vous et évitez les activités physiques intenses pendant 24 heures." } }, { "@type": "Question", "name": "Comment se préparer psychologiquement ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Préparez-vous en vous informant sur le traitement et en discutant avec des professionnels." } }, { "@type": "Question", "name": "Quelles conditions traitent l'oxygénation hyperbare ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Elle traite des conditions comme la maladie de décompression, les infections et les brûlures." } }, { "@type": "Question", "name": "Comment se déroule une séance d'oxygénation ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Une séance se déroule dans une chambre pressurisée où le patient respire de l'oxygène pur." } }, { "@type": "Question", "name": "Quelle est la durée d'une séance ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Une séance dure généralement entre 60 et 120 minutes, selon la condition traitée." } }, { "@type": "Question", "name": "Y a-t-il des effets secondaires ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Les effets secondaires peuvent inclure des douleurs aux oreilles, des nausées ou des troubles visuels." } }, { "@type": "Question", "name": "Qui peut administrer ce traitement ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Le traitement doit être administré par des professionnels de santé formés en médecine hyperbare." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des lésions pulmonaires, des convulsions et des infections." } }, { "@type": "Question", "name": "Comment gérer une embolie gazeuse ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Une embolie gazeuse nécessite une intervention rapide, souvent avec une oxygénation hyperbare." } }, { "@type": "Question", "name": "Quels risques liés à l'oxygénation hyperbare ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Les risques incluent des barotraumatismes, des troubles de la vision et des réactions allergiques." } }, { "@type": "Question", "name": "Comment prévenir les infections en chambre ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Pour prévenir les infections, maintenez une bonne hygiène et suivez les protocoles de désinfection." } }, { "@type": "Question", "name": "Quels signes d'une complication grave ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Des signes comme des douleurs thoraciques intenses ou des troubles neurologiques nécessitent une attention immédiate." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque de décompression ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent la profondeur de plongée, la durée et l'absence de pauses de sécurité." } }, { "@type": "Question", "name": "Qui est à risque d'intoxication à l'oxygène ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Les plongeurs et les patients recevant une oxygénation hyperbare à haute pression sont à risque." } }, { "@type": "Question", "name": "Quels antécédents augmentent les risques ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Des antécédents de troubles respiratoires ou neurologiques peuvent augmenter les risques." } }, { "@type": "Question", "name": "Comment l'âge influence-t-il les risques ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Les personnes âgées peuvent avoir un risque accru de complications en raison de la fragilité des tissus." } }, { "@type": "Question", "name": "Quels médicaments augmentent les risques ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Certains médicaments, comme les diurétiques, peuvent augmenter le risque de déshydratation et de complications." } } ] } ] }

Sources (10000 au total)

Functionalized biomimetic nanoparticles combining programmed death-1/programmed death-ligand 1 blockade with photothermal ablation for enhanced colorectal cancer immunotherapy.

Immune checkpoint blockade therapy targeting programmed death-1 (PD-1) or its major ligand programmed death-ligand 1 (PD-L1) has achieved remarkable success in the treatment of several tumors, includi...

Clinical Benefit of First-Line Programmed Death-1 Antibody Plus Chemotherapy in Low Programmed Cell Death Ligand 1-Expressing Esophageal Squamous Cell Carcinoma: A Post Hoc Analysis of JUPITER-06 and Meta-Analysis.

Pembrolizumab or nivolumab plus chemotherapy was approved as a first-line treatment for high programmed cell death ligand 1 (PD-L1)-expressing esophageal squamous cell carcinoma (ESCC) by the European... Post hoc analysis of the Chinese JUPITER-06 study focusing on efficacy stratified by PD-L1 tumor proportion score (TPS; using JS311 antibody) was conducted. Electronic databases were searched to ident... The post hoc analysis of JUPITER-06 showed more prominent clinical benefit with PD-1 antibody plus chemotherapy than with chemotherapy alone in both the high and low PD-L1-expressing subgroups. Five r... This study provided novel evidence supporting the superiority of PD-1 antibody plus chemotherapy to chemotherapy alone in patients with advanced ESCC with low PD-L1 expression. Further studies of pred...

Association between programmed death-1 pathway and major depression.

Major depression (MD) may be associated with inflammation and immunity. PD-1 (programmed death-1), PD-L1 (programmed death-ligand 1) and PD-L2 (programmed death-ligand 2) are among the inhibitory immu... During a period of 2 years, patients with MD and healthy controls were recruited from a medical centre in this study. The diagnosis of MD was established according to the DSM-5 criteria. The severity ... A total of 54 patients with MD and 38 healthy controls were recruited. According to the analyses, there is a significantly higher PD-L2 level in MD than in healthy controls and lower PD-1 level after ... It was found that PD-1 pathway might play an important role in MD. We need a large sample to prove these results in the future....

Programmed cell death protein 1 is a marker for neoadjuvant chemotherapy response in triple-negative breast cancer.

Tumor-infiltrating lymphocytes are detectable in up to 75% of triple-negative breast cancer. The composition of these infiltrates may influence prognosis and is not known regarding regulatory or effec... This was a retrospective observational study. Clinical and pathological data from 38 triple-negative breast cancer patients treated with neoadjuvant chemotherapy at the University Hospital (HUCFF/UFRJ... Statistically significant changes in stromal tumor-infiltrating lymphocyte categories were observed before and post-neoadjuvant chemotherapy, with 32% of intermediate cases becoming high. The correlat... In this study, we observed that chemotherapy significantly increases stromal tumor-infiltrating lymphocytes, CD8 T cells, as well as CD8/FoxP3 ratio. Most importantly, programmed cell death protein 1 ...